Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study
- Hyo Jin Kim1,
- Hyunsuk Kim1,
- Nara Shin1,
- Ki Young Na2,
- Yong Lim Kim3,
- Daejung Kim4,
- Jae Hyun Chang5,
- Young Rim Song6,
- Young-Hwan Hwang7,
- Yon Su Kim1,
- Curie Ahn1,
- Joongyub Lee8,
- Kook-Hwan Oh1Email author and
- Representing the Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowering Effect Of iPTH Level (CUPID) Study Group
© Kim et al.; licensee BioMed Central Ltd. 2013
Received: 21 February 2013
Accepted: 14 May 2013
Published: 25 May 2013
Elevated serum level of fibroblast growth factor-23 (FGF23) is associated with adverse outcomes in dialyzed patients.
The CUPID study compared the efficacy of a cinacalcet-based regimen with conventional care (vitamin D and P binders) for achieving the stringent NKF-K/DOQI targets for peritoneal dialysis (PD) patients. Additionally, we analyzed change in FGF23 levels between two treatments to explore the cinacalcet effect in lowering FGF23.
Multicenter, open-labeled, randomized controlled study.
Seven university-affiliated hospitals in Korea.
Overall, 66 peritoneal dialysis patients were enrolled.
Sixty six patients were randomly assigned to treatment with either cinacalcet + oral vitamin D (cinacalcet group, n = 33) or oral vitamin D alone (control group, n = 33) to achieve K/DOQI targets. CUPID included a 4-week screening for vitamin D washout, a 12-week dose-titration, and a 4-week assessment phases. We calculated mean values of iPTH, Ca, P, Ca x P, during assessment phase and final FGF23 to assess the outcome.
Main outcome measures
Achievement of >30% reduction of iPTH from baseline (primary) and FGF23 reduction (secondary).
72.7% (n = 24) of the cinacalcet group and 93.9% (n = 31) of the control group completed the study. Cinacalcet group received 30.2 ± 18.0 mg/day of cinacalcet and 0.13 ± 0.32 μg/d oral vitamin D (P < 0.001 vs. control with 0.27 ± 0.18 μg/d vitamin D). The proportion of patients who reached the primary endpoint was not statistically different (48.5% vs. 51.5%, cinacalcet vs. control, P = 1.000). After treatment, cinacalcet group experienced a significant reduction in FGF23 levels (median value from 3,960 to 2,325 RU/ml, P = 0.002), while an insignificant change was shown for control group (from 2,085 to 2,415 RU/ml). The percent change of FGF23 after treatment was also significantly different between the two groups (− 42.54% vs. 15.83%, P = 0.008). After adjustment, cinacalcet treatment was independently associated with the serum FGF23 reduction.
Cinacalcet treatment was independently associated with the reduction of FGF23 in our PD patients.
Controlled trials NCT01101113
KeywordsCinacalcet Fibroblast growth factor 23 Peritoneal dialysis
Fibroblast growth factor-23 (FGF23) is an endocrine hormone that regulates phosphate and vitamin D homeostasis. FGF23 is synthesized and secreted by bone cells, mainly osteocytes and plays a role as a phosphatonin by binding to klotho/FGF-receptor complex [1, 2]. FGF23 inhibits phosphate reabsorption in the renal tubule and promotes phosphaturia by down-regulating sodium-phosphate co-transporters . It decreases renal production of 1,25(OH)2D by inhibiting 1α-hydroxylase and up-regulating 24-hydroxylase in the proximal tubule [3, 4]. As kidney function decreases in chronic kidney disease (CKD) patients, FGF23 increases progressively in order to regulate phosphate homeostasis . In advanced CKD, FGF23 no longer maintains phosphate homeostasis and the suppression of 1,25(OH)2D production exerted by FGF23 induces PTH elevation, resulting in secondary hyperparathyroidism (SHPT). Several studies reported that high levels of FGF23 are related to left ventricular hypertrophy [6–9] and progression of chronic kidney disease . Furthermore, FGF23 elevation is associated with increased mortality in CKD and ESRD patients . Therefore, in CKD patients, modulation of FGF23 could possibly be a therapeutic target in preventing morbidity and mortality. Cinacalcet hydrochloride is a novel calcimimetics that acts by allosteric binding to the calcium sensing receptor on the parathyroid cell membrane and thus lowering PTH. To date, several studies reported that cinacalcet reduced FGF23 in predialysis or hemodialysis patients [12, 13].
It was shown that FGF23 levels are independently correlated with serum concentrations of P, Ca x P, and serum parathyroid hormones (PTH). Recently, a few clinical trials on the efficacy of cinacalcet on the lowering of PTH exhibited that cinacalcet treatment lowers FGF23 in ESRD patients [12, 13]. However, above studies have not elucidated whether FGF23 suppression during cinacalcet treatment is mediated indirectly via the modulation of serum P and PTH or directly by cinacalcet per se. The aim of the Cinacalcet study for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect Of iPTH Level (CUPID) Trial (NCT01101113, registered at the http://www.clinicaltrials.gov) is to investigate the effectiveness of a cinacalcet-based regimen versus vitamin D based regimen in treating SHPT, controlling PTH, Ca, and P levels for achieving the K/DOQI targets for peritoneal dialysis (PD) patients. Additionally, we also investigated whether the cinacalcet effect on the FGF23 suppression occurs directly, independent of its modulation of Ca, P, PTH and exposure to vitamin D.
Seven university-affiliated hospitals in Korea participated in the CUPID trial. Patients were considered for the study if they were ≥18 and ≤70 years of age, had received peritoneal dialysis (PD) for ≥3 months and with pre-screening intact PTH (iPTH) ≥300 pg/ml (≥250 pg/ml if they had been taking vitamin D analogs) and albumin–corrected calcium ≥9.0 mg/dl. After a 4-week washout period during which vitamin D was withheld, iPTH and calcium levels were measured again. Patients with post-washout iPTH ≥300 pg/ml and corrected calcium ≥9.0 mg/dl were finally enrolled in the study.
Patients were excluded if they had acute inflammatory disease within 3 months, chronic inflammatory disease, gastrointestinal bleeding within 3 months, and were pregnant or breast feeding. Patients who had been taking azole antifungal agents, macrolide antibiotics, amiodarone, tricyclic antidepressant, vinca alkaloid, bupropion antipsychotics, calcitonin, biosphosphonate, steroid hormones, or benzodiazepine drugs were excluded. The study adhered to the principles of the Declaration of Helsinki. The independent ethics committee for each participating center (Seoul National University Hospital Institutional Review Board; Seoul National University Bundang Hospital Institutional Review Board; Kyungpook National University Hospital Institutional Review Board; Samsung Medical Center Office of Research Subjects Protection; Gachon University Gil Medical Center Institutional Review Board; Hallym University Sacred Heart Hospital Institutional Review Board/Ethics Committee; Eulji University Hospital Institutional Review Board) approved the study protocol, and all patients provided written informed consent.
Study design and treatments
The control group received flexible dose of oral active vitamin D to achieve K/DOQI targets for PTH, Ca, P, and Ca × P. For active vitamin D, only oral calcitriol, not active vitamin D analogs, was prescribed for both groups. Phosphate binders were allowed to be prescribed at the physician’s discretion throughout the study for both groups. The subjects were not allowed to change dialysate calcium concentration during the entire study period and could not change cinacalcet and vitamin D dosage during the efficacy-assessment phase.
Biochemical determinations and FGF23
PTH was measured by intact PTH assays at 4-week intervals. All centers were instructed to use the same type of PTH assay throughout the entire study period. Serum Ca, P, and albumin level were measured every 4 weeks but measured twice at 2-week interval if the dose of cinacalcet was changed. ‘Baseline values’ of the various biochemical tests – Ca, P, iPTH, etc. - were defined as those measured after washout period (post-washout).
FGF23 levels were determined at baseline (post-washout) and at the end of assessment phase. Second generation human FGF23 (C-terminal) ELISA kit (Immutopics, San Clemente, California, USA) was employed. The serum was diluted ten-fold with dilution reagent to measure C- terminal FGF23, since the assay accuracy was not validated above this dilution level. The assay range was between 1.5 and 14,900 RU/ml. Over-range of FGF23 which could be not detected after dilution, were excluded in the analysis: 2 patients in the cinacalcet group at baseline; 1 in the control group at baseline; 1 in the control group at efficacy assessment phase.
Study end points
The mean values of corrected Ca, P, and corrected Ca × P during assessment period were calculated to analyze the results. The primary endpoint was the achievement of >30% reduction of iPTH from baseline. The secondary end points were the absolute or percent change of FGF23 from baseline and the achievements of the K/DOQI targets for the iPTH (150~300 pg/ml), Ca (8.4 ~ 9.5 mg/dL), P (3.5 ~ 5.5 mg/dL), Ca x P (<55 mg2/dL2), and composite of above targets. We estimated target enrollment to be 85 subjects (based on α= 0.05, β=0.2, and 10% drop-out rate) in order to prove more than 32% difference between the treatment and control arms in the achievement of the primary end point .
Baseline demographic and mineral metabolic parameters were analyzed: differences in gender and underlying diseases between treatment groups were evaluated with χ2 tests; patient’s age, duration of dialysis, and baseline parameters were evaluated with independent samples t-tests. Results are presented as mean ± SD for normally distributed variables and median [interquartile range (IQR)] for variables with skewed distributions. A log and square root transformation was used to normalize variability of the iPTH and FGF23 data distribution, respectively; log and square root transformation were implemented before entry into analysis. The demographic variables, percent change in Ca, P, log-transformed iPTH, and the vitamin D dose were used for univariate analysis. Variables showing a significant association (P <0.01) in the univariate analysis or of considerable theoretical relevance were retained as potential predictors in the multivariate model (enter method). Percent change measures were chosen for analysis to alleviate the biasing effect of the patient’s baseline mineral metabolic levels. The percent change was calculated for each mineral metabolic parameter with the following formula: [(week 16 measurement – baseline measurement)/baseline measurement] × 100. Percent changes of the log iPTH and the square root FGF23 were calculated similarly: [(log week 16 measurement – log baseline measurement)/log baseline measurement] × 100; [(square root week 16 measurement – square root baseline measurement)/square root baseline measurement] × 100. Whether or not the pretreatment (post-washout) FGF23 levels would anticipate the probability of achieving an iPTH in the range between 150 and 300 pg/ml during the efficacy assessment phase, were evaluated by logistic regression analysis. P values <0.05 were considered to represent statistical significance. All statistical analyses were performed using the SPSS software (version 18.0., SPSS Inc, Chicago, III, USA).
Study population and baseline parameters
Patient demographics and baseline laboratory values
Cinacalcet group (n = 33)
Control group (n = 33)
Sex, n (%)
25 to 71
28 to 64
Duration of dialysis, months mean (SD)
Medical history, n (%)
peripheral vascular disease
congestive heart failure
iPTH, median (Q1,Q3) (pg/ml)*
729 (518, 1424)
649 (490, 1143)
Serum calcium, mean (SD) (mg/dL)*
Serum phosphorus, mean (SD) (mg/dL)*
Ca X P, mean (SD) (mg2/dL2)*
Serum FGF23 (Q1,Q3) (RU/ml)*
3960 (2430, 6609)
2085 (741, 7182)
Renal Kt/V (Q1, Q3)
0.0 (0.0, 0.1)
0.0 (0.0, 0.5)
Peritoneal Kt/V (SD)
Total Kt/V (SD)
Overall, twenty four (72.7%) of the cinacalcet group and thirty one (93.9%) of the control group completed the study. Reasons for dropouts included adverse reactions (n = 3 vs. 0, cinacalcet vs. control), withdrawal of consent (n = 3 vs. 1), kidney transplant (n = 2 vs. 1) and taking not allowed medication (n = 1 vs. 0). No subjects in the control group took cinacalcet throughout the study period.
PTH and biochemical parameters
The proportion of patients who achieved Ca × P <55 mg2/dl2 (54.5% vs. 51.5%, P = 1.000), the Ca target (54.5% vs. 45.5%, P = 0.623), and P target (30.3% vs. 30.3%, P = 1.000) were similar. In the cinacalcet group, the Ca × P increased by 5.1% (P = 0.324 vs. control with 14.4%) and P increased by 8.3% in the cinacalcet group (P = 0.909 vs. control with 7.3%). Only the change of calcium was significantly different (−7.2% vs. 1.1%, cinacalcet vs. control, P <0.001).
The proportion of patients who achieved K/DOQI targets for iPTH, Ca, P, Ca × P, and their composite were not statistically different between two groups.
Effect of cinacalcet on the FGF-23
Univariate linear regression analysis for association of the percent change in square root FGF23 with other variables
Sex (male vs. female)
−27.03 to 34.62
Age (per 1year)
−1.16 to 2.18
DM (yer vs. no)
−16.24 to 64.96
Treatment (cinacalcet vs control)
−70.96 to −13.93
Vitamin D dose (per 1μg/day)
−49.86 to 63.15
−1.64 to 2.19
−1.40 to 2.02
−0.46 to 0.41
Univariate and multivariate linear regression analysis for association of the percent change in square root FGF23 with treatment groups
B coefficient* (95% CI)
−42.45 (−70.96 to −13.93)
−43.58 (−73.07 to −14.09)
Within the cinacalcet group, there was no significant difference in baseline FGF23 levels between the subjects who achieved iPTH target and those who did not [3870 RU/ml (1100, 5108 RU/ml) vs. 4159 RU/ml (2433, 7376 RU/ml), P = 0.427].
Doses of medications and safety
A total of 51.5% of the cinacalcet group and 33.3% of the control group experienced at least one adverse event. The most common adverse reactions were digestive symptoms. In the cinacalcet group, nausea/vomiting (18.2%), dyspepsia (3.0%), diarrhea (3.0%), and constipation (3.0%) were present. For the control group, nausea/vomiting, and diarrhea (3.0%, each) were most often observed. There were no significant differences in both groups. Other adverse reactions in the cinacalcet group were tingling sensation (6.1%), general weakness (3.0%), and headache (6.1%). There was no death or other serious adverse events in the entire study period in both groups. Severe hypocalcemia (serum corrected calcium <7.5 mg/dl at least once during the entire study period) occurred in one patient (3.0%) of each group, respectively. However, there was no symptomatic, or fatal hypocalcemia in both groups. All safety analyses were performed by intention-to-treat method.
The purpose of the present study was to investigate the effectiveness of cinacalcet-based vs. vitamin D based regimen in treating SHPT, achieving the K/DOQI targets for PD patients, and the cinacalcet effect on FGF23 suppression. The present study did not show a difference in the reduction of iPTH since it did not achieve the target enrollment number. However, the present study exhibited that serum FGF23 was significantly reduced during cinacalcet treatment. Moreover, cinacalcet effect on the FGF23 suppression was independent of its effect on serum iPTH, Ca, P, and the exposure to oral vitamin D.
Recent studies have shown that high levels of FGF23 are associated with poor outcomes such as left ventricular hypertrophy [15, 16], progression of CKD  and increased overall mortality . FGF23 could be a better prognosis predictor of cardiovascular disease than any other biomarkers. Therefore, reduction of FGF23 may become a novel target of treating SHPT for lowering cardiovascular risk and improving prognosis of CKD patients.
It is well documented in a few recent randomized clinical trials that cinacalcet is more efficient than conventional vitamin D based therapy in treating SHPT in hemodialysis patients [14, 18, 19]. Furthermore, post hoc analysis of these studies reported that cinacalcet modulated FGF23 reduction. However, the specific mechanism of cinacalcet effect on FGF23 suppression has not been elucidated. Therefore, it remains to be investigated whether cinacalcet lowers FGF23 per se or indirectly via modulating other mineral metabolic parameters. Several studies showed that the cinacalcet group received lower dose of vitamin D and exhibited lower level of PTH, compared with those receiving conventional vitamin D based therapy [14, 18]. It is well known that PTH and vitamin D stimulate FGF23 production [20–22]. Therefore, one could postulate that the suppression of FGF23 in the cinacalcet group may be associated with lower exposure to vitamin D and lower level of PTH. Koizumi et al.  allowed relatively constant dosage of vitamin D during the study period. Since the dosage of vitamin D was allowed to be titrated according to the biochemical parameters in the present study, the cinacalcet group was prescribed with lower dose of vitamin D than the control group. However, in our univariate analysis, neither vitamin D dose nor other mineral metabolic parameters such as iPTH, Ca and P were associated with FGF23 change. Cinacalcet treatment was independently associated with FGF23 reduction, after adjustment to the age and sex. One could postulate that cinacalcet per se might have a modulatory effect on the FGF23 level.
The mechanism underlying the more direct association of FGF23 reduction with cinacalcet is yet unclear. FGF23 is synthesized and released by bone cells, mainly osteocytes [1, 2]. Osteocyte and osteoblast were shown to express calcium sensing receptor (CaSR). Cinacalcet acts mainly by allosteric binding to the CaSR on the parathyroid cell membrane for regulating calcium homeostasis. Whether cinacalcet directly acts on the CaSR at the bone cells to regulate FGF23 secretion needs to be investigated.
The strengths of this study include prospective, randomized study and a design to follow change of FGF23 levels in PD patients with cinacalcet treatment, compared with conventional vitamin D treatment. Moreover, unlike other study reporting an effect of cinacalcet on the FGF23 reduction , the present study showed an independent association between cinacalcet treatment and FGF23 reduction. Unlike the EVOLVE trial, there was no possibility of cross-over of medication between the two arms, since cinacalcet was not commercially available in Korea during the study period .
However, the present study has a limitation of a small sample size and an open-labeled study. The investigators of the CUPID Study finished the recruitment prematurely before target number of enrollment was reached. This was because enrollment was delayed due to lack of subjects who fulfilled the strict inclusion criteria. This resulted in lack of statistical power to prove a difference in the iPTH reduction between two groups, which was the primary endpoint of the present study. Besides, the prescribed dose of cinacalcet was 30.2 ± 18.0 mg/day during assessment phase, which means our subjects received lower dose of cinacalcet than that reported in other studies [14, 18]. This might be another explanation for the negative result as regards to the primary end point. Cinacalcet group exhibited more drop-outs that the control group. The analysis of FGF23 change was performed on a per-protocol basis. This may have resulted in a selection bias because only subjects who were more tolerable to the medication were included in the analysis. Dietary phosphorus intake, which is another determinant of serum FGF23 in CKD [24, 25] could not be assessed in the present study. However, there were no significant differences the prescribed dose of oral phosphate binders and serum P levels between the two groups (data not shown). Therefore, we could postulate that the dietary P intake was similar between the two groups, although the present study did not analyze dietary phosphorus intake.
The present study might suggest a more direct association between serum FGF23 and cinacalcet treatment, independent from other mineral metabolic parameters and vitamin D dose. Mechanistic research is warranted on the specific mechanism of FGF23 reduction by cinacalcet.
Fibroblast growth factor 23
Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect Of iPTH Level
National kidney foundation kidney disease outcomes quality initiative
Intact parathyroid hormone
Chronic kidney disease
Enzyme linked immunosorbent assay
Calcium sensing receptor
The CUPID study was funded by Kyowa Kirin, Korea. However, the funding body had no role in the design, implementation, analysis of the study. Presented at the Kidney Week 2012 of the American Society of Nephrology, San Diego, CA, October 30- November 4, 2012. We thank the Medical Research Collaborating Center (MRCC), Seoul National University Hospital for the statistical advice.
Funded by Kyowa Kirin, Korea.
- Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006, 444: 770-774. 10.1038/nature05315.View ArticlePubMed
- Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997, 390: 45-51. 10.1038/36285.View ArticlePubMed
- Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, Miyamoto K, Fukushima N: Human fibroblast growth factor-23 mutants suppress Na+−dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem. 2003, 278: 2206-2211. 10.1074/jbc.M207872200.View ArticlePubMed
- Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004, 19: 429-435.View ArticlePubMed
- Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011, 79: 1370-1378. 10.1038/ki.2011.47.PubMed CentralView ArticlePubMed
- Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009, 119: 2545-2552. 10.1161/CIRCULATIONAHA.108.844506.PubMed CentralView ArticlePubMed
- Hsu HJ, Wu MS: Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci. 2009, 337: 116-122. 10.1097/MAJ.0b013e3181815498.View ArticlePubMed
- Seiler S, Cremers B, Rebling NM, Hornof F, Jeken J, Kersting S, Steimle C, Ege P, Fehrenz M, Rogacev KS, Scheller B, Bohm M, Flister D, Heine GH: The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J. 2011, 32: 2688-2696. 10.1093/eurheartj/ehr215.View ArticlePubMed
- Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE: Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009, 207: 546-551. 10.1016/j.atherosclerosis.2009.05.013.View ArticlePubMed
- Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler R: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study. J Am Soc Nephrol. 2007, 18: 2600-2608. 10.1681/ASN.2006080936.View ArticlePubMed
- Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011, 305: 2432-2439. 10.1001/jama.2011.826.PubMed CentralView ArticlePubMed
- Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD: Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrology. 2010, 5: 110-116. 10.2215/CJN.03630509.View Article
- Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M: Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2012, 27: 784-790. 10.1093/ndt/gfr384.View ArticlePubMed
- Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, Ling X, Goodman WG, Turner S, Charytan C: Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol. 2008, 3: 1718-1725. 10.2215/CJN.01040308.PubMed CentralView ArticlePubMed
- Kirkpantur A, Balci M, Gurbuz OA, Afsar B, Canbakan B, Akdemir R, Ayli MD: Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrol Dial Transplant. 2011, 26: 1346-1354. 10.1093/ndt/gfq539.View ArticlePubMed
- Seiler S, Heine GH, Fliser D: Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Supplement. 2009, 114: S34-S42.View Article
- Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008, 359: 584-592. 10.1056/NEJMoa0706130.PubMed CentralView ArticlePubMed
- Messa P, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazao JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wikie M, Zani VJ, Molemans B, Carter D, Locatelli F: The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008, 3: 36-45. 10.2215/CJN.03591006.PubMed CentralView ArticlePubMed
- Sprague SM, Evenepoel P, Curzi MP, Gonzalez MT, Husserl FE, Kopyt N, Sterling LR, Mix C, Wong G: Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol. 2009, 4: 1465-1476. 10.2215/CJN.06141108.PubMed CentralView ArticlePubMed
- Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD: Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006, 17: 1305-1315. 10.1681/ASN.2005111185.View ArticlePubMed
- Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, Ikeda K, Fujimori A, Fukagawa M: Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract. 2005, 101: c94-c99. 10.1159/000086347.View ArticlePubMed
- Donate-Correa J, Muros-de-Fuentes M, Mora-Fernandez C, Navarro-Gonzalez JF: FGF23/Klotho axis: phosphorus, mineral metabolism and beyond. Cytokine Growth Factor Rev. 2012, 23: 37-46. 10.1016/j.cytogfr.2012.01.004.View ArticlePubMed
- Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012, 367: 2482-2494.View ArticlePubMed
- Ferrari SL, Bonjour JP, Rizzoli R: Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2005, 90: 1519-1524.View ArticlePubMed
- Antoniucci DM, Yamashita T, Portale AA: Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrine Metab. 2006, 91: 3144-3149. 10.1210/jc.2006-0021.View Article
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/14/112/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.